Vertex Pharma (VRTX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Vertex Reports Second-Quarter 2017 Financial Results
July 26, 2017 4:01 PM EDT-Second-quarter 2017 cystic fibrosis product revenues of $514 million; $324 million for ORKAMBI and $190 million for KALYDECO-
-Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&D and SG&A expenses-
-Pipeline of investigational CF medicines continues to progress and expand to support goal of treating all people with CF-
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2017. Vertex reiterated its full-year 2017 financial guidance... More
